Navigation Links
Cheaper, more effective treatment of type 1 Gaucher disease possible
Date:10/19/2010

Researchers at Yale School of Medicine have found that new disease pathways involving more than one cell type leads to Type 1 Gaucher disease, a rare genetic disorder in which fatty substances called glycosphingolipids accumulate in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased risk of cancer and Parkinson's disease.

The new findings could lead to less expensive and more effective ways to treat the disorder, which affects about 1 in 50,000 people in the general population. Those of Eastern and Central European (Ashkenazi) Jewish heritage are at highest risk for the disease, with 1 in 750 affected. The results are published in the October 18 issue of Proceedings of the National Academy of Sciences.

Treatment for Type 1 Gaucher diseasethe type that does not cause a rare and fatal neurodegenerative childhood diseaseinvolves expensive recombinant enzyme infusions every two weeks for life, which on average cost $200,000 per year. Gaucher disease symptoms are unpredictable, even among affected siblings. "In order to tailor treatment to individuals, we need an improved understanding of the disease mechanisms," said senior author of the study, Pramod Mistry, M.D., professor of pediatrics and internal medicine at Yale School of Medicine.

For almost 20 years, investigators around the world have tried and failed to develop mouse models of Type 1 Gaucher disease that replicate the human disease faithfully. Mistry and his team were able to develop a mouse model that replicates all of the features of the human disease.

It was previously thought that the disease affects only one cell type in the body called macrophages. "In our study we show that all cell types are involved and lipids that accumulate trigger abnormal signaling resulting in the malfunction of many cell types," said Mistry. "This helps explain aspects of the disease, such as osteoporosis, cancer risk, and risk of Parkinson's disease, all of which did not respond to macrophage-directed enzyme therapy. With this knowledge, we can look forward to developing treatments that are directed not only to macrophages, but to all cell types involved in the disease process."

Mistry and his team have just started enrolling patients in an international trial of a small molecule substrate inhibitorin the form of a pill, which was developed by Genzyme Corporation. "Because it is a pill and will affect all cell types, we expect it to reverse all, not just part, of the disease. Also, it should be less expensive than enzyme treatment," he said.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

Related biology news :

1. Tires made from trees -- better, cheaper, more fuel efficient
2. Orange peels, newspapers may lead to cheaper, cleaner ethanol fuel
3. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
4. Commercial aquatic plants offer cost-effective method for treating wastewater
5. RNA molecules, delivery system improve vaccine responses, effectiveness
6. Cost-effective farm waste-to-energy technology focus of research
7. New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning
8. New study indicates smallpox vaccination effective for decades
9. Fractional dose of scarce meningitis vaccine may be effective in outbreak control
10. Flame retardants prove ineffective on fresh-cut Christmas trees
11. Flame retardants prove ineffective on fresh-cut Christmas trees
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cheaper, more effective treatment of type 1 Gaucher disease possible
(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... 22, 2016 SuperCom (NASDAQ:   ... for the e-Government, Public Safety, HealthCare, and Finance sectors announced today ... been selected to implement and deploy a community-based supportive services program ... California , further expanding its presence in the state. ... This new program, which ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... , Jan. 23, 2017  Recognizing the need ... scientific discovery and solutions, the University of Miami ... Institutes for Science and Engineering to achieve those ... (STEM) to help solve some of the world,s ... President Julio Frenk unveiled the network ...
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)... , Jan. 23, 2017 /PRNewswire/ - Resverlogix Corp. ... results from the New Zealand ... patients. The data showed remarkable results in reducing inflamed ... healthy control patients. It is believed that this is ... connection of this type can be made between epigenetic ...
(Date:1/23/2017)... ... January 23, 2017 , ... AxioMed will be presenting its ... meeting in Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting ... to experience the simplicity of the surgical technique,” said Jake Lubinski, President of ...
Breaking Biology Technology: